ENDURENCT06270719
An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion moved earlier from Dec 31, 2029 to Dec 31, 2028
- Eligibility criteria expanded, about 13 words
- Primary endpoints: details revised at 1 of 2 entries
- Trial sites expanded: 25 → 29 locations
- Notable Eligibility criteria expanded, about 54 words
- Primary endpoints: 1 to 2
- Secondary endpoints: 8 to 11
- Study title expanded, about 1 word
- Minor Study sites: 22 to 25v12
- Minor Study sites: 19 to 22v11
- Minor Trial status: Recruiting to Enrolling by Invitation
- Study sites: 17 to 19
Show 8 earlier versionsHide 8 earlier versions
- Minor Study sites: 15 to 17v9
- Minor Study sites: 13 to 15v8
Notable Eligibility criteria expanded, about 6 wordsv7 Show 4 more changesShow less
- Primary endpoint revised
- Study sites: 9 to 13
- Interventions: Standard of Care (Drug), delandistrogene moxeparvovec (Genetic) to Delandistrogene Moxeparvovec (Genetic), Standard of Care (Drug)
- Secondary endpoints: 9 to 8
- Minor Study sites: 6 to 9v6
- Minor Study sites: 5 to 6v5
- Minor Study sites: 4 to 5v4
- Minor Study sites: 1 to 4v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 29, 2024 to Feb 7, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Cohort 1: participants prescribed ELEVIDYS in a commercial setting. Cohort 1a (Ambulatory ELEVIDYS Prospectively Treated Cohort): participants prescribed ELEVIDYS by commercially treating physicians with consent no later than 30 days from infusion. All participants will be dosed with ELEVIDYS based on United States prescribing information (USPI). The Post Market Requirement (PMR) Cohort (sub-cohort of 1a) consists of participants with laboratory data as specified in the ELEVIDYS USPI. Cohort 1b (Non-ambulatory ELEVIDYS Prospectively Treated Cohort): non-ambulatory DMD participants prescribed ELEVIDYS commercially and recruited by treating physicians before infusion (enrollment currently closed). Cohort 1c (ELEVIDYS Retrospectively Treated Cohort): participants dosed with ELEVIDYS with complete baseline data within 6 months prior to dosing and complete prospectively collected annual follow-up data after infusion until the time of cohort entry (sponsor approval required for enrollment).
Cohort 2: ambulatory DMD participants who are at least 4 years of age at baseline, unexposed to DMD gene therapy, and receiving or prescribed chronic glucocorticoids at study entry.
Genetic: Delandistrogene Moxeparvovec
Drugs: Standard of Care
Sites
29 sites in 1 country